Literature DB >> 9145434

Neuropeptide Y family of hormones: receptor subtypes and antagonists.

A A Balasubramaniam1.   

Abstract

Neuropeptide Y (NPY) is the most abundant peptide present in the mammalian central and peripheral nervous system. NPY exhibits a variety of potent central and peripheral effects including those on feeding, memory, blood pressure, cardiac contractility and intestinal secretions. Classical pharmacological studies have shown that NPY effects are mediated by four different receptor subtypes, Y-1, Y-1-like, Y-2, and Y-3. However, the existence of numerous atypical activities provide strong evidence for the occurrence of additional NPY receptor subtypes. Pharmacological studies have further been facilitated by the recent cloning and expression of Y-1, Y-2, Y-4 (PP-1) and Y-5 receptors. Moreover, the cloned Y-5 receptor has been suggested to be the long awaited Y-1-like receptor involved in feeding. Structure-activity studies have laid a good foundation towards the development of receptor selective compounds, and to date potent Y-1 selective peptide and nonpeptide antagonists have been developed. The need to clone numerous receptor subtypes and to develop receptor selective compounds for physiological and perhaps clinical use is expected to keep NPY research active for many years to come.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9145434     DOI: 10.1016/s0196-9781(96)00347-6

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  20 in total

1.  Conservation of expression of neuropeptide Y5 receptor between human and rat hypothalamus and limbic regions suggests an integral role in central neuroendocrine control.

Authors:  K A Nichol; A Morey; M H Couzens; J Shine; H Herzog; A M Cunningham
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

Review 2.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening.

Authors:  Shaun P Brothers; S Adrian Saldanha; Timothy P Spicer; Michael Cameron; Becky A Mercer; Peter Chase; Patricia McDonald; Claes Wahlestedt; Peter S Hodder
Journal:  Mol Pharmacol       Date:  2009-10-16       Impact factor: 4.436

Review 4.  Neuropeptide Y in normal eating and in genetic and dietary-induced obesity.

Authors:  B Beck
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

5.  Differential modulation of synaptic transmission by neuropeptide Y in rat neocortical neurons.

Authors:  Alberto Bacci; John R Huguenard; David A Prince
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

Review 6.  Physiological and Therapeutic Roles of Neuropeptide Y on Biological Functions.

Authors:  Pravin Shende; Drashti Desai
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

7.  Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater bone mineral density.

Authors:  K L Seldeen; P G Halley; C H Volmar; M A Rodríguez; M Hernandez; M Pang; S K Carlsson; L J Suva; C Wahlestedt; B R Troen; S P Brothers
Journal:  Neuropeptides       Date:  2017-11-07       Impact factor: 3.286

8.  Neuropeptide Y modulates effects of bradykinin and prostaglandin E2 on trigeminal nociceptors via activation of the Y1 and Y2 receptors.

Authors:  J L Gibbs; A Diogenes; K M Hargreaves
Journal:  Br J Pharmacol       Date:  2006-12-04       Impact factor: 8.739

9.  Neuropeptide Y is a prejunctional inhibitor of vagal but not sympathetic inotropic responses in guinea-pig isolated left atria.

Authors:  A P Serone; J A Angus
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

10.  A study of NPY-mediated contractions of the porcine isolated ear artery.

Authors:  R E Roberts; D A Kendall; V G Wilson
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.